Compound ID | 1864
Synonym(s): S-4661
Class: Beta-lactam
| Agent Type: | Semisynthetic; Small molecule; Direct acting; |
| Spectrum of activity: | Gram-positive & Gram-negative |
| Mechanism of action: | Cell wall synthesis inhibitor. Binds to bacterial penicillin-binding proteins (PBP) and interferes with bacterial cell wall integrity and synthesis; carbapenems bind to all PBPs, with PBP2 and PBP4 as the highest-affinity targets; carbapenems have a very broad spectrum including non-fermenters and are not hydrolysed by most beta-lactamases with exception of carbapenemases; PBP inhibitor |
| Description: | Semisynthetic, derived from thienamycin. Similar to meropenem |
| Institute where first reported: | Shionogi Inc |
| Year first mentioned: | 2003 |
| Highest development stage: | Approved by FDA in 2007 |
| Development status: | Active |
| Reason dropped: | In treating patients with pneumoniae, doripenem showed increased risk of death and lower clinical cure rates compared to imipenem and cilastatin for injection |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/73303 |
| Guide to Pharmacology: | doripenem |
| Citations: |
|